Abstract Development of a highly effective vaccine or antibodies for the prevention and
ultimately elimination of malaria is urgently needed. Here we report the isolation of a number …

Immunization with attenuated Plasmodium falciparum sporozoites (PfSPZs) has been shown
to be protective against malaria, but the features of the antibody response induced by this …

The circumsporozoite protein of the human malaria parasite Plasmodium falciparum
(PfCSP) is the main target of antibodies that prevent the infection and disease, as shown in …

Combinations of monoclonal antibodies (mAbs) against different epitopes on the same
antigen synergistically neutralize many viruses. However, there are limited studies …

Plasmodium falciparum malaria contributes to a significant global disease burden.
Circumsporozoite protein (CSP), the most abundant sporozoite stage antigen, is a prime …

Antibodies against the central repeat of the Plasmodium falciparum (Pf) circumsporozoite
protein (CSP) inhibit parasite activity and correlate with protection from malaria. However …

Potent and durable vaccine responses will be required for control of malaria caused by
Plasmodium falciparum (Pf). RTS, S/AS01 is the first, and to date, the only vaccine that has …

Studies in animals and human volunteers demonstrate that antibodies against the repeat-
region of the Plasmodium circumsporozoite protein (CSP) abrogate sporozoite infection …

The N-terminal domain of the circumsporozoite protein (CSP) has been largely neglected in
the search for a malaria vaccine in spite of being a target of inhibitory antibodies and …

Acquired resistance against antimalarial drugs has further increased the need for an
effective malaria vaccine. The current leading candidate, RTS, S, is a recombinant …